Managing Chronic Itch: New Approaches and Treatment Protocols

Gyllenberg Wiens^*
*Correspondence: Gyllenberg Wiens, Department of Dermatology, University of Rome, Italy, Email:

Introduction

Chronic itch, also known as pruritus, is a common and often debilitating condition that can significantly affect a person's quality of life. Unlike acute itch, which is typically a temporary response to an irritant or allergen, chronic itch persists for six weeks or more and can be a symptom of various underlying dermatological, systemic, or neurological conditions. These conditions include eczema, psoriasis, atopic dermatitis, kidney disease, and even certain cancers. Chronic itch can lead to severe discomfort, sleep disturbances, and secondary skin infections from excessive scratching. Despite its widespread impact, managing chronic itch has been challenging for clinicians, as traditional treatments such as antihistamines or topical corticosteroids often provide limited relief and may cause undesirable side effects with prolonged use. As a result, there has been increasing interest in developing new approaches and treatment protocols that target the underlying mechanisms of itch, offering more effective and sustainable relief for patients. [1]

 

Moreover, the integration of personalized treatment approaches, based on individual skin types and underlying health conditions, is becoming an essential aspect of managing chronic pruritus. These advances not only offer hope for improved relief but also promise to revolutionize how chronic itch is approached in clinical practice. [2]

Description

One of the most promising new approaches in managing chronic itch is the use of Janus kinase (JAK) inhibitors. JAK inhibitors work by blocking specific enzymes involved in the immune response, particularly those that contribute to the inflammation and pruritus seen in conditions like atopic dermatitis, psoriasis, and chronic urticaria. These inhibitors target cytokines, which play a key role in triggering itch sensations, thus preventing the cascade of inflammatory processes that lead to chronic itching. Drugs such as abrocitinib, upadacitinib, and baricitinib have been shown to provide significant relief from chronic itch in clinical trials, with patients experiencing a reduction in both itch intensity and skin lesions. This class of drugs represents a breakthrough in itch management because they specifically target the underlying immune dysregulation rather than just masking symptoms. Although these drugs are still being evaluated for long-term safety, they offer a promising option for patients with chronic pruritus who have not responded to conventional treatments.

Conclusion

The management of chronic itch has evolved significantly in recent years, with new approaches and treatment protocols offering more targeted and effective solutions. Traditional treatments like antihistamines and corticosteroids often fail to provide lasting relief, leading to the development of novel therapies that address the underlying biological mechanisms of pruritus. The emergence of JAK inhibitors and monoclonal antibodies has revolutionized the way chronic itch is treated, offering more sustainable options for patients with immune-driven conditions like atopic dermatitis and psoriasis. These therapies specifically target the immune and inflammatory pathways that contribute to chronic itch, reducing both the intensity of itching and the associated skin damage.

References

1. Himmerich, Hubertus, and Khadijeh Mirzaei. "Body Image, Nutrition, and Mental Health." Nutrients 16 (2024): 1106.

Google Scholar, Crossref, Indexed at

2. Jáuregui-Lobera, Ignacio, Patricia Bolaños-Ríos and Inmaculada Ruiz-Prieto. "Thoughtâ??shape fusion and body image in eating disorders." Int J Gen Med (2012): 823-830

Google Scholar, Crossref, Indexed at